US EditionPublished • loading... • Updated
Aspen Neuroscience Enters Phase 3 Trials
Summary by San Diego Business Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Aspen Neuroscience Enters Phase 3 Trials
SAN DIEGO – Aspen Neuroscience is set to launch a pivotal Phase 3 trial in early 2026 for its personalized cell therapy candidate for the treatment of Parkinson’s Disease following the company’s latest funding round. ANPD001 is an autologous cell therapy drug, meaning it’s developed using healthy cells from a patient that are extracted and […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
